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INTRODUCTION 
 
Acute myocardial infarction 
Acute myocardial infarction (AMI) is the leading cause of death in developed 
countries and presents a major public health problem (1). It mainly occurs after 
coronary artery occlusion as a result of loss of myocardial tissue blood supply (2). 
Myocardial tissue that no longer receives adequate blood dies rapidly and is replaced 
with poorly functioning or non-functional fibrotic scar tissue which can expand 
leading to increased loss of functional myocardial tissue, which in turn can result in a 
dysfunctional heart (3). More than one-half of a million people experience a first AMI 
each year in the United States, and over two hundred thousand people suffering from 
myocardial infarction die before reaching a hospital. 
Treatments for AMI are typically effective only if implemented rapidly after occlusion 
of the coronary vessel (4). Aggressive thrombolytic therapies include drugs that 
dissolve thrombi or primary angioplasty and stents (5). Chronic, post-infarction 
treatments include angiotensin-converting enzyme inhibitors, beta blockers, diuretics 
and calcium channel antagonists, which can reduce aortic pressure; thereby 
decreasing ventricular remodeling of the left ventricle (LV) that otherwise can expand 
the size of the infarct leading to more non-functional scar tissue. Open-heart surgical 
methods include coronary artery bypass surgery to repair or replace occluded 
coronary vessels and methods to repair, shrink, or remove the non-functional infarcted 
region of heart tissue. 
 
BMP1 isoforms 
Bone morphogenetic protein 1 (BMP1) was originally isolated from highly purified 
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BMP bovine bone extracts and was reported to induce formation of cartilage in vivo in 
a subcutaneous bone formation assay (6). However, BMP1 does not share significant 
amino acid sequence homology with other BMPs, which are members of the TGFβ 
super family of growth factors. BMP1 was shown to be identical to procollagen C-
proteinase, which is a zinc metalloproteinase that cleaves the carboxyl pro-domains of 
procollagens I, II and III to produce mature monomers of the major fibrillar collagens 
I, II and III (7).  
This event is essential for the proper assembly of insoluble collagen within the 
extracellular matrix (ECM) and the formation of scar tissue as found associated with a 
variety of organ disorders. In addition to its role in cleaving procollagen, BMP1 
cleaves other ECM macromolecules, including prolysyl oxidase (8), probiglycan (9) 
and prolaminin-5 (10). The BMP1 is now known to be an essential control point of 
morphogenesis during the cascade of pattern formation (11). Mice null for the BMP1 
gene are perinatal lethal with failure of ventral body wall closure and persistent gut 
herniation, probably due to defective ECM and limited disruption of dorsoventral 
patterning (12). Consistent with a loss of pCP activity, BMP1-null mice have 
abnormal collagen fibrils. BMP1/TLD-related metalloproteinases are responsible for 
the proteolytic maturation of a numerous of extracellular proteins related to formation 
of the ECM. These include various collagens, small leucine-rich proteoglycans, lysyl 
oxidase and laminin-5 (13). The originally discovered form of BMP1 is designated as 
“BMP1-1” and other BMP1 isoforms encoded by splice variant RNA transcripts have 
been described on the transcriptional level and designated with sequential suffixes: 
BMP1-2, BMP1-3, BMP1-4, BMP1-5, BMP1-6, and BMP1-7 (14). As expected, the 
BMP1 isoforms encoded by the splice variant transcripts share a number of domains, 
including leader peptide, proregion, and protease (catalytic) region. Recently, a 
4 
number of BMP1 isoforms have been confirmed at the protein level as circulating in 
the blood of patients with various diseases, such as chronic kidney disease and acute 
pancreatitis, and in the blood of healthy human individuals, which only contains 
BMP1-3 (15). Moreover, the role of BMP1-3 in processing procollagen and possibly 
leading to fibrosis and scar tissue in a variety of diseases is an attractive target for 
developing new therapies. 
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HYPOTHESIS 
 
The intricate relationships among the cellular and acellular components of the heart 
drive the proper heart development, homeostasis and recovery following pathological 
injury. Cellular myocytes, fibroblasts and endothelial cells differentially express and 
respond to particular extracellular matrix factors that contribute to cell communication 
and overall cardiac function. ECM facilitates mechanical, electrical and chemical 
signals during homeostasis and the developmental process. These signals modulate 
cellular activities such as cell proliferation, migration, adhesion and changes in the gene 
expression. During various physiological cardiac states different cellular and ECM 
expression changes take place (16). For example, during myocardial infarction 
myocytes undergo apoptosis, fibroblasts undergo intensive proliferation, vascular 
density decreases and an increased expression of collagen I, III, IV, fibronectin and 
periostin leads to enhanced fibrosis and diminished cardiac function. These processes 
have adverse effects on left ventricular function, thus forming a therapeutic basis for use 
of anti-fibrotic agents to inhibit or reverse such adverse effects (17).  
Fibrosis diseases account for up to 45% of deaths in the developed world, yet there 
are no approved antifibrotic therapies (18). Translating advances in experimental 
fibrosis to clinical use has been challenging in the past, because there are now many 
candidate antifibrotic targets, and most are tested usually only in a single organ type 
and species. The discovery of circulating organ specific BMP1 isoforms represents a 
ground-breaking finding in the field of fibrosis-related human diseases. Exploration of 
their structure/function relationship and characterization of their potential for 
processing target substrates, as well as their role in the regulation of the activity of 
growth factors, specifically morphogens from the TGFβ superfamily, could be of 
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major medical importance.  
BMP1-3 in the circulation might have multiple, yet unpredicted functions in 
orchestrating the ECM assembly globally and locally in regulating latent growth 
factors activity affecting the pathophysiology of major human diseases with fibrosis 
as a common outcome. BMP1 is involved in the biosynthetic processing of a range of 
ECM precursors and releases several TGFβ superfamily members, including BMP2 
and BMP4, growth and differentiation factors GDF 8/11, and TGFβ1 from their latent 
complexes or antagonists. These dual roles have fuelled speculation that BMP1 
proteinases orchestrate ECM assembly by signaling through TGFβ-like proteins. 
Today, conventional therapy for AMI are not specific for cardiac fibrosis, but are 
aimed to improve heart function, mainly by preventing/reducing ventricular 
remodeling (ACE inhibitors, aldosterone antagonists, β blockers) or 
preventing/reducing progression of coronary artery disease (antiplatelet drugs and 
statins). Despite the fact that there are 544 currently ongoing cardiovascular clinical 
trials, out of which 342 are related to drugs and 157 to various drug targets, there are 
no effective and safe drugs or therapies to treat fibrosis.   
Therefore, we hypothesize that BMP1-3 represents a core pathway protein essential in 
fibrotic events following acute myocardial infarction and its targeting may be 
sufficient to limit fibrosis progression. Moreover, administration of an monoclonal 
antibody to BMP1-3 could be effective in decreasing the extent of myocardial tissue 
damage and even to promote regeneration of functional myocardial tissue in the 
infarcted region. Furthermore validation of our novel target molecules and the 
development of neutralizing antibodies as therapeutic options to prevent fibrosis after 
AMI would represent a major step forward. 
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CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSION  
 
Until recently, regeneration of the heart was thought to be restricted to fish and 
amphibians which retain a robust capacity for cardiac regeneration throughout life. It 
has been shown in zebrafish that genetic regulatory hierarchy of developing 
myocardium involves a close relationship between cardiac precursors and specific 
signaling molecules, including GATA, BMP and Nkx (19). Hearts of zebrafish can 
regenerate completely by proliferation and differentiation of mature cardiac myocytes 
within two months of surgical amputation of up to 20% of the ventricle (20, 21), but 
this is not the same in the adult mammals. Recently, it has been found that the hearts 
of neonatal mice can regenerate by cardiomyocyte proliferation after partial surgical 
resection, but this capacity is lost by seven days of age (22). Several studies have 
shown evidence for cardiac stem cell populations within the postnatal mammalian 
heart, likely to form cells with cardiac myocyte properties in culture and after 
transplantation back into the heart (23). At least one of these progenitor populations 
contributing to endogenous repair are the cells of the epicardium (24). Although it is 
unlikely to expect that regeneration of cardiac tissue in humans will be as effective as 
in amphibians and fish, prevention of scar formation and control of its degradation 
may now be a realistic option. We hypothesize that inhibition of BMP1-3, when given 
to rats with AMI, influences the scar size and composition eventually preventing an 
excessive scar formation. It is also not known whether the scar composed of less 
collagens I-III and more other ECM will make it prone to future reverse remodeling 
and/or replacing fibrous with regenerated muscle tissue. Interestingly, in line with 
this, amphibians and fish following heart injury and limb amputation do not form 
scars, but cover the injured surface by a layer of epithelial cells and little extracellular 
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matrix which is not composed of cross-linked collagens. Therefore, the role of BMP1-
3 in heart repair following a heart injury model in zebrafish will also be interesting 
issue. 
Recently was shown that current approaches to drug target discovery are not fully 
successful in identifying relevant and specific targets (25). Our hypothesis suggests a 
different point, utilizing proteomic analysis and exploring target proteins with already 
proven preliminary in vivo efficacy. Based on our preliminary findings we will 
characterize, validate and test BMP1 isoforms, as new targets for AMI and develop 
neutralizing antibodies as new therapeutic tools. 
The advancement of the current knowledge will be primarily achieved by gathering 
information about BMP1 isoforms molecular structure and biochemical properties. 
For that purpose it will be necessary to produce labelled recombinant protein isoforms 
and altered protein forms to characterize the specific amino acids critical for substrate 
binding. This knowledge will be utilized for engineering specific therapeutic 
antibodies against individual BMP1 isoforms. Additionally, applying proteomic and 
genomic approaches to generate the expression profiles of organ proteins in the course 
of myocardial infarction, it will be able to identify BMP1 isoform extra cellular 
targets in animal experiments using the existing and newly made specific acute 
myocardial infarction models. These newly identified proteins will present the “first 
line” target molecules for exploring the BMP1 isoform specific substrate candidates 
and the mechanism of action. 
If this step will be successful, it will be able to construct diagnostic tools based on 
protein probes for the BMP1 isoforms. Since fibrogenesis is both a systemic and a 
local disease, each organ has a specific pathophysiology of fibrosis and it is unlikely 
that one molecule might prevent the progress of fibrosis. Therefore, a better 
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understanding of the role of individual BMP1 isoform – BMP1-3 will enable to test it 
in preventing the disease progress. This new, risky and innovative approach should be 
applied in treating myocardial fibrotic conditions. 
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